Trienbio Introduces CELLAELE™ HO-Cera PT1 for Advanced Skin Care

The global cosmetics market is shifting from simple surface hydration and single active ingredient applications to advanced drug delivery system (DDS) technologies aimed at precise ingredient delivery. Current consumer demand is for multifunctional care that addresses epidermal hydration and dermal elasticity within a single formulation, known as Longevity Beauty.

Existing technologies face clear limitations. Conventional liposomes primarily focus on encapsulating water-soluble ingredients, while naturally derived oleosomes, due to their micro-size (1-3 μm), often remain on the surface without penetrating the skin deeply.

To overcome these technical limits, Trienbio has introduced the CELLAELE™ HO-Cera PT1, a next-generation smart fusion delivery system that uniquely combines oleosome and liposome technologies, garnering significant market attention.

Oleosomes, referred to as 'nature's liposomes,' are lipid storage entities used by plants for sprouting. Composed of a monolayer of phospholipids and oleosin proteins, they efficiently preserve the integrity of neutral fats under environmental stress, offering excellent stability and enabling sustained release without chemical emulsifiers.

Trienbio has recognized the moisture-retaining capabilities of oleosomes and completed 'Hybrid Oleo Tech' by integrating nanotransmission technology. Utilizing a microfluidizer, the firm has developed a formulation where both micro and nano-sized delivery systems coexist, creating a unique dual action mechanism that cares for the skin both superficially and deeply.

CELLAELE™ HO-Cera PT1's effectiveness derives from two core active ingredients tailored to its hybrid structure: Ceramide NP for epidermal barrier care and Palmitoyl Tripeptide-1 for dermal elasticity. The ceramide is encapsulated at high concentrations within micro oleosomes, ensuring gradual release to rebuild damaged skin barriers, significantly reducing transepidermal water loss (TEWL).

Palmitoyl Tripeptide-1, a water-soluble ingredient, integrates with nanosome structures to penetrate the stratum corneum, stimulating collagen formation and inhibiting collagen-degrading enzymes. Clinical data show a robust increase in ECM recovery characteristics with this peptide, confirming a promising synergistic mechanism that enhances barrier integrity and hydration.

Clinical trials validating CELLAELE™ HO-Cera PT1's performance demonstrated significant results: a 110.55% improvement in moisture retention after 24 hours, a 134.07% increase in skin density after four weeks, and approximately 70% improvement in crow's feet after four weeks of bi-daily application.